Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Also referred to as 'MEDI2070'Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 240-Product Name: BrazikumabProduct Code: MEDI2070Pharmaceutical Form: Solution for injection/infusionINN or Proposed INN: BRAZIKUMABCAS Number: 1610353-18-8Other descriptive name: Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody----1件: 97 💬
2BRAZIKUMAB1件: Brazikumab (Brazikumab)1件: Brazikumab (Brazikumab) 💬 1件: IL23A 💬 9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97 💬
3Brazikumab high dose1件: Brazikumab (Brazikumab)1件: Brazikumab (Brazikumab) 💬 1件: IL23A 💬 9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
4Brazikumab Induction Dose1件: Brazikumab (Brazikumab)1件: Brazikumab (Brazikumab) 💬 1件: IL23A 💬 9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97 💬
5Brazikumab IV Infusion1件: Brazikumab (Brazikumab)1件: Brazikumab (Brazikumab) 💬 1件: IL23A 💬 9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
6Brazikumab low dose1件: Brazikumab (Brazikumab)1件: Brazikumab (Brazikumab) 💬 1件: IL23A 💬 9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
7Brazikumab Maintenance Dose1件: Brazikumab (Brazikumab)1件: Brazikumab (Brazikumab) 💬 1件: IL23A 💬 9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97 💬
8Brazikumab SC Injection1件: Brazikumab (Brazikumab)1件: Brazikumab (Brazikumab) 💬 1件: IL23A 💬 9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96 💬
9BrazikumabProduct Code: MEDI2070Pharmaceutical Form: Solution for injection/infusion in pre-filled syringeINN or Proposed INN: BRAZIKUMABCAS Number: 1610353-18-8Other descriptive name: Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody----1件: 97 💬